Skip to main content

MINI REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1454833
This article is part of the Research Topic Harnessing Single-Cell Insights: Pioneering Predictive Markers for Immunotherapy Efficacy in Solid Tumors View all 8 articles

A Single-Cell Perspective on Immunotherapy for Pancreatic Cancer: From Microenvironment Analysis to Therapeutic Strategy Innovation

Provisionally accepted
Rui Wang Rui Wang 1,2Jie Liu Jie Liu 1,2Bo Jiang Bo Jiang 1,2*Benjian Gao Benjian Gao 1,2Hong h. Luo Hong h. Luo 3*Fengyi Yang Fengyi Yang 1,2*Yuntao Ye Yuntao Ye 1,2*Zhuo Chen Zhuo Chen 1,2*Hong Liu Hong Liu 1,2*Cheng Cui Cheng Cui 1,2*Ke Xu Ke Xu 4*Bo Li Bo Li 1,2*Xiaoli Yang Xiaoli Yang 1,2*
  • 1 Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
  • 2 Academician (Expert) Workstation of Sichuan Province, Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, The Affiliated Hospital of Southwest Medical University, Luzhou, China
  • 3 Department of Radiology, Xichong County People's Hospital, Nanchong, China
  • 4 Department of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China

The final, formatted version of the article will be published soon.

    Pancreatic cancer remains one of the most lethal malignancies, with conventional treatment options providing limited efficacy. Recent advancements in immunotherapy have offered new hope, yet the unique tumor microenvironment (TME) of pancreatic cancer poses significant challenges to its successful application. This review explores the transformative impact of single-cell technology on the understanding and treatment of pancreatic cancer. By enabling high-resolution analysis of cellular heterogeneity within the TME, single-cell approaches have elucidated the complex interplay between various immune and tumor cell populations. These insights have led to the identification of predictive biomarkers and the development of innovative, personalized immunotherapeutic strategies. The review discusses the role of single-cell technology in dissecting the intricate immune landscape of pancreatic cancer, highlighting the discovery of T cell exhaustion profiles and macrophage polarization states that influence treatment response. Moreover, it outlines the potential of single-cell data in guiding the selection of immunotherapy drugs and optimizing treatment plans. The review also addresses the challenges and prospects of translating these single-cell-based innovations into clinical practice, emphasizing the need for interdisciplinary research and the integration of artificial intelligence to overcome current limitations. Ultimately, the review underscores the promise of single-cell technology in driving therapeutic strategy innovation and improving patient outcomes in the battle against pancreatic cancer.

    Keywords: Pancreatic Cancer, Immunotherapy, Single-cell technology, Tumor Microenvironment, predictive biomarkers, personalized treatment

    Received: 25 Jun 2024; Accepted: 08 Oct 2024.

    Copyright: © 2024 Wang, Liu, Jiang, Gao, Luo, Yang, Ye, Chen, Liu, Cui, Xu, Li and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Bo Jiang, Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
    Hong h. Luo, Department of Radiology, Xichong County People's Hospital, Nanchong, China
    Fengyi Yang, Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
    Yuntao Ye, Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
    Zhuo Chen, Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
    Hong Liu, Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
    Cheng Cui, Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
    Ke Xu, Department of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China
    Bo Li, Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
    Xiaoli Yang, Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.